Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Preferentially Expressed Antigen of Melanoma (PRAME)
- Target
- PRAME
- Molecular classification
- Leucine-rich repeat proteins, Cancer/Testis Antigen (CTA)
01
Overview
Preferentially expressed antigen of melanoma (PRAME) is a cancer/testis antigen (CTA) predominantly expressed in melanomas and some other cancers, with limited expression in normal adult tissues except for testis. It represses retinoic acid signaling, inhibiting differentiation and apoptosis. PRAME serves as a diagnostic marker to distinguish between malignant melanoma and benign nevi and is a promising target for immunotherapy due to its selective overexpression profile across malignancies.
02
Mechanism of action
PRAME-specific immunotherapy, vaccines, and cellular immunotherapies are being investigated
03
Biological functions
Represses retinoic acid signalingInhibits differentiationInhibits apoptosisEpithelial-to-mesenchymal transition (EMT) induction
04
Disease associations
Cancer
05
Safety considerations
Potential for off-target effects due to expression in testisImmunotherapy-related adverse events
06
Biomarkers
PRAME expression in tumor tissue
Beyond the preview
Go deeper on Preferentially Expressed Antigen of Melanoma (PRAME).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Preferentially Expressed Antigen of Melanoma (PRAME).